Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
China’s biggest supplier of temperature-controlled services for the drug sector has renewed a Hong Kong listing plan, raising questions with hefty pre-IPO payouts Key Takeaways: Turnover has grown steadily, driven…
RELATED ARTICLES
-
Yueshi Digital’s name belies its agribusiness focus
-
Can New Hope Dairy out-milk Mengniu and catch up with Yili?
002946.SHE
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Kinwong runs hot on AI boom, cold on plunging margins
603228.SHG
- Unsated by Hong Kong listing, Knowledge Atlas seeks more funds in Shanghai
- Beneath the radar: How Chinese solar makers and IPO hopefuls are surviving the turbulent U.S. market
- Insilico revenue soars above $100 million on AI drug partnerships
